Gossamer Bio (NASDAQ:GOSS) Given Buy Rating at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 264.96% from the company’s previous close.

GOSS has been the topic of several other research reports. Wall Street Zen raised Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Gossamer Bio Stock Up 5.4%

Shares of GOSS opened at $2.74 on Thursday. The firm has a market capitalization of $634.20 million, a PE ratio of -3.97 and a beta of 1.92. The firm has a 50-day moving average price of $3.09 and a 200 day moving average price of $2.58. Gossamer Bio has a 52-week low of $0.76 and a 52-week high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The company had revenue of $13.29 million for the quarter, compared to the consensus estimate of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. On average, equities analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Gossamer Bio during the 2nd quarter valued at $26,000. Ciovacco Capital Management LLC acquired a new stake in shares of Gossamer Bio during the third quarter worth $27,000. Banco BTG Pactual S.A. purchased a new stake in shares of Gossamer Bio during the second quarter valued at $27,000. Drive Wealth Management LLC boosted its position in shares of Gossamer Bio by 52.7% in the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock valued at $31,000 after purchasing an additional 8,797 shares during the period. Finally, Brighton Jones LLC acquired a new position in shares of Gossamer Bio in the 3rd quarter valued at $36,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.